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Abstract
Purpose of review: Niemann-Pick disease type C
(NP-C) is a neurovisceral disorder that may be more
prevalent than earlier estimates. Diagnosis of NP-C
is often delayed; a key aim for clinical practice is to
reduce this delay. Recently, substantial progress
has been made in the field of NP-C screening and
diagnosis, justifying an update to the existing recom-
mendations for clinical practice. Recent findings:
New biomarker profiling and genetic analysis tech-
nologies are included as first-line diagnostic tests
for NP-C. Most diagnoses can now be confirmed by
combination of biomarker and genetic analyses.
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Filipin staining may facilitate diagnosis in uncertain cases. Recommendations are provided
for psychiatrists, neuro-ophthalmologists, and radiologists, and on screening within specific
at-risk patient cohorts. The NP-C diagnostic algorithm has been updated and simplified.
Summary: This publication provides expert recommendations for clinicians who may see
patients presenting with the signs and symptoms of NP-C, including general practitioners,
pediatricians, neurologists, and psychiatrists. Neurol Clin Pract 2017;7:499–511
N
iemann-Pick disease type C (NP-C) is a rare neurovisceral lysosomal disorder
caused by autosomal recessive mutations in NPC1 or NPC2 (95% and ;4%
of patients).1,2 Analysis of 4 independent exome sequencing databases gave a con-
servative estimated incidence of 1/92,104 for NP-C1 and 1/2,858,998 for NP-C2,
in agreement with recent clinical data. After accounting for 2 common NPC1 variants, the
incidence was estimated to be potentially 1/19,000–1/36,000 for late-onset forms, suggesting
that previous prevalence estimates may be too low.3 NP-C diagnosis is typically delayed by
a mean of 4.1 years from first onset of neurologic symptoms,4 narrowing the therapeutic window.
The first international recommendations for clinical management of NP-C were prepared in
2009 based on a literature review and consensus among an expert panel5 with updates in 2012
after a second meeting of an NP-C Guidelines Working Group.1 Recent advances in the field
of NP-C screening technologies (e.g., biomarkers) and diagnostic techniques (e.g., molecular
genetics) justify an update of these recommendations. The development and availability of
simple, rapid, and reliable biomarkers (oxysterols,6–8 lysosphingomyelin derivatives,9,10 and
bile acids11,12) will likely increase detection of patients with NP-C. Increased availability of
next-generation sequencing (NGS) (e.g., phenotype-specific gene panels13) may widen the
application of genetic testing in clinical practice, particularly in at-risk patient cohorts.14
Previous recommendations focused on identifying individual patients with a high clinical
suspicion of NP-C. Technologic developments may facilitate patient identification based on
clinical suspicion or within larger cohorts via broad genetic or biomarker screening, which ul-
timately may improve patient outcomes.
Development of the updated NP-C diagnostic recommendations
The NP-C Diagnostic Recommendations Expert Panel met in May 2016 to assess the impact
of recently published data and to reach consensus on the best approaches to diagnosing NP-C.
The following sections of the previous recommendations were updated: differential diagnosis
and initial detection, diagnosis, and the NP-C diagnostic algorithm. Three approaches to
the detection and diagnosis of patients with NP-C were established: clinical assessment, bio-
marker testing, and genetic analysis.
Differential diagnosis and initial detection
• All patients with suspicion of NP-C require rigorous and detailed clinical assessment, as
described in the 2012 diagnostic recommendations.1
• All undiagnosed patients with any manifestation of NP-C should be referred to regional
or national centers specializing in inherited metabolic disorders.
• Visceral, neurologic, ophthalmologic, and psychiatric manifestations should be explored
in depth.1
• Details of the signs, symptoms, and disease stages of NP-C are covered extensively
elsewhere.1,2,15
Advances in psychiatric assessments
• Psychiatric symptoms and cognitive disorders were observed in 45% and 61%, respec-
tively, of patients with late-onset NP-C,16 and psychiatric symptoms in 86% of patients
in another small cohort17; however, no specific neuropsychiatric profile was observed.
Patients with NP-C, particularly adults, can present with a range of psychiatric symptoms,
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most commonly cognitive impairment (decline in executive function, memory, and psy-
chomotor speed), schizophrenia-like symptoms (frequently with atypical features), and
mood disorders. These symptoms can overshadow other symptoms of NP-C.
• Owing to the inherent difficulties in examining patients in psychiatric practice, and
incomplete or inaccurate medical histories, populations of adult patients displaying
neuropsychiatric symptoms may be enriched for NP-C.18
Advances in ocular motor assessment
• Eye movements (saccades, smooth pursuit, gaze-holding function, optokinetic nystag-
mus, and vergence) should be examined (neurocular.com). Impaired vertical saccades,
commonly referred to as vertical supranuclear gaze palsy (VSGP) yet correctly termed
vertical supranuclear saccade palsy (VSSP), are of particular importance in NP-C as one
of the first and most frequent signs in patients with NP-C.19
• Slow vertical saccades are often masked by blinking; the eyelids must be lifted during
examination.
• As the disease progresses, VSGP emerges. It is typically followed by impairment in
horizontal saccades and then horizontal gaze.
• Video-oculography allows the recording of all types of eye movements and can be used
for quantitative analysis of ocular motor function (eyeseecam.com/).
• VSSP may be present before visceral, neurologic, or psychiatric manifestations occur and is
sometimes the only symptom of NP-C in adults, representing a highly sensitive and
specific sign.19
Advances in clinical tools
• The NP-C Suspicion Index (NP-C SI)20 quantitates the diagnostic weight of NP-C signs
and symptoms, individually and in combination.
• The updated NP-C SI features 2 age-specific indices (#4 and .4 years of age
[npc-si.com/]).15,21
• The 2-out-of-3 suspicion index can be used to provide a rapid assessment of NP-C
suspicion in patients presenting with early-onset ataxia.22
At-risk clinical patient groups
• The clinical manifestations of NP-C may be nonspecific (e.g., ataxia), implying that
patients with NP-C may be “hidden” within larger at-risk clinical patient cohorts, termed
here and elsewhere14 as clinical niches, who also present with nonspecific signs and
symptoms.14 NP-C should therefore be considered as a differential diagnosis for patients
in these at-risk groups.
• We defined several at-risk clinical patient groups, detailed below and summarized in
table 1.
Ataxia
• Ataxia is a common but nonspecific sign of NP-C.4,23,24 Early-onset ataxia, ataxia in
combination with other clinical symptoms25 (“ataxia plus”; see table 1), ataxia without
neuropathy, or ataxia of unknown etiology are suggestive of NP-C.
Intellectual disability and developmental delay
• Patients with NP-C presenting with intellectual disability and developmental delay
(ID/DD) typically have other manifestations (e.g., liver abnormalities in infancy, spleno-
megaly) or neurologic signs (e.g., ataxia or dystonia).
• Detailed history and examination should exclude NP-C as a cause of ID/DD.
• Further genetic and biomarker investigation are mandatory when consanguinity, family
history of unexplained neurologic disease, or focal neurologic or visceral signs are present.
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Cognitive impairment and early-onset cognitive decline
• The majority of patients with NP-C show impaired cognitive function.4,23
• Early (,65 years of age) cognitive decline is frequently observed in patients with NP-C,
particularly in those who also present with early-onset ataxia.25
Dystonia
• Dystonia is a relatively common presenting feature in patients with NP-C, particularly
in juvenile or adult neurologic onset.4
• For patients presenting with focal idiopathic dystonia, or dystonia in combination with
VSSP, cognitive decline, or psychiatric disturbances (“dystonia plus”; see table 1), NP-C
should be considered as a potential diagnosis.
• Myoclonus, chorea, or tremor may also occur.
Frontotemporal dementia
• Patients with NP-C show symptoms of progressive dementia, impaired cognitive func-
tioning, and behavioral problems2 consistent with those observed in frontotemporal
dementia.26
• The degree of overlap between the symptoms of frontotemporal dementia and NP-C
suggests that this patient group warrants screening for NP-C.
Atypical schizophrenia/early-onset psychosis
• Schizophrenia-like psychosis is relatively common in patients with NP-C.17,27
Table 1 Clinical patient groups with an increased risk of Niemann-Pick disease type C (NP-C)
Clinical patient group with an increased
risk of NP-C Signs to look out for
Ataxia Early-onset ataxia (onset ,40 years of age)
“Ataxia plus”: VSSP, dystonia; cognitive decline; atypical psychiatric disturbances;
optional extensor plantar reflexes rather than genuine spastic paraparesis; as well
as mental retardation
Ataxia without neuropathy
Ataxia of unknown etiology
Intellectual disability and developmental
delay
Visceral signs, e.g., (hepato-)splenomegaly
Subtle movement dysfunction (ataxia/dystonia), VSSP
Cognitive impairment and early-onset
cognitive decline
,40 years of age, neurologic signs (e.g., ataxia, VSSP, dystonia)
Dystonia Generalized dystonia
,40 years of age
“Dystonia plus”: VSSP, cognitive decline, or psychiatric disturbances




Neurologic signs (e.g., ataxia, VSSP, dystonia)
Organic features: visual hallucinations, comorbid cognitive impairment
Visceral symptoms in the pediatric
population
Isolated infantile splenomegaly or cholestasis or hepatosplenomegaly or fetal/
neonatal ascites and neurologic signs (e.g., ataxia, VSSP, dystonia)
Abbreviation: VSSP 5 vertical supranuclear saccade palsy.
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• Additional signs include early onset of mental confusion and cognitive impairment,
hallucinations (visual being more important than other sensory components), catatonia,
and resistance to antipsychotic treatment.27
• Co-occurrence of psychosis and any other neurologic signs should raise suspicion of an
organic cause, with NP-C as a differential diagnosis.
Visceral symptoms in the pediatric population
• NP-C should be considered in the differential diagnosis of children with visceral symptoms
such as hepatosplenomegaly, isolated splenomegaly, prolonged unexplained neonatal
Figure Revised Niemann-Pick disease type C (NP-C) diagnostic algorithm for the use of
biomarkers and genetic testing
Individual steps can be omitted if not locally available. aAt-risk patient populations are defined in table 1. bNegative
biomarkers may be suggestive that the diagnosis is not NP-C. cSingle-gene sequencing (exons or known muta-
tions) or other. d11 Variant of unknown significance optional. eCovers deep intronic sequencing and if possible
gene transcription regulatory regions. fTwo different alleles. gBiomarker(s) profiling (if not initially conducted), or
extended biomarkers profiling (in addition to those already conducted). Despite comprehensive investigations, it
may not be possible to definitively confirm a diagnosis of NP-C in a few patients. In such cases, a thorough
reappraisal of longitudinal clinical data, more in-depth genomic analyses (e.g., whole exome and whole genome
sequencing), and cell biological assessments could be considered. cDNA 5 complementary DNA; MLPA 5multiplex
ligation-dependent probe amplification.
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jaundice lasting .2 weeks with conjugated hyperbilirubinemia, and acute neonatal liver
failure,1 as such symptoms can be the initial manifestation of NP-C.2
• Visceral findings are common in other metabolic diseases.1
Neuroimaging tests
• MRI and PET may be useful, but are not specific for NP-C.
• MRI findings commonly include atrophy of the cerebellum and cortex (particularly
frontal zones) in more advanced disease, but this may be absent in early stages.
• Segmentation of subcortical structures may demonstrate volumetric reductions in the
thalamus and hippocampus.28
• PET commonly shows hypometabolism of the thalamus and cerebellum.29
• Absence of abnormal MRI findings does not exclude a diagnosis of NP-C. Changes in
MRI findings are highly variable, nonspecific, and of uncertain sensitivity.
Diagnosis
Biomarkers
• Biomarker screening methods can now be considered a first-line step in the NP-C
diagnostic process (figure).
• Compared with the filipin staining test, biomarkers have several advantages, including
noninvasiveness, rapidity, higher throughput, lower cost, and ease of use (regarding sample




• Oxysterols (cholesterol oxidation products) are the most established, accessible, and
widely used biomarkers, with the largest evidence base to support their reliability and
sensitivity for NP-C.30
• Cholestane-3b,5a,6b-triol (C-triol) and 7-ketocholesterol (7-KC) were shown to be
elevated in plasma from patients with NP-C.6–8
• C-triol is the preferred oxysterol biomarker, with superior specificity and sensitivity for
NP-C compared with 7-KC.8,31 C-triol values for the upper quartile of NP-C carriers
overlap with those of patients with NP-C.
• Elevated C-triol and 7-KC levels occur in other diseases, mainly NP-A and NP-B, and
acid lipase deficiency30–32; therefore, elevated oxysterol levels should be interpreted with
caution.
• Prolonged storage of samples at room temperature can lead to autoxidation of choles-
terol, which may cause false-positive results.7
Other currently validated biomarkers
• Newer biomarkers may one day eclipse oxysterols. Desirable qualities include increased
stability, more convenient sampling methods (e.g., dried blood spot [DBS] or urine), smaller
blood volumes needed (e.g., DBS with infants), more convenient handling, and character-
istic NP-C profiles facilitating differential diagnosis when used in multianalyte panels.30,33
Lysosphingomyelin-509 and other lysosphingolipids
• Lysosphingomyelin-509 (Lyso-SM-509) is elevated in plasma from patients with NP-C
and NP-A/B compared with controls.9,33
• The increase of Lyso-SM in patients with NP-C is very small compared with that of
patients with NP-A/B; therefore, measurement of combinations of biomarkers, such as
Lyso-SM and Lyso-SM-509, allows distinction between NP-C and sphingomyelinase
deficiencies (NP-A/B).30,33 In the future, additional derivatives of Lyso-SM and
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multianalyte panels may be able to further differentiate between NP-A/B, NP-C, and
other related diseases.
Bile acids
• Specific bile acids have been found to be elevated in patients with NP-C. The analytical
species of choice is 3b,5a,6b-trihydroxy-cholanoyl-glycine.11,12 The assay is applicable
to DBS, plasma, and urine, and preanalytical auto-oxidation is not a concern.11,12
• 3b,5a,6b-trihydroxy-cholanoyl-glycine appears to be more specific for NP-C than
C-triol; other than NP-C, it is only known to be elevated in NP-A/B, and it better
discriminates NP-C carriers from patients.11,12
When and in whom to use biomarkers
Any/all biomarkers should be tested as early as possible in the following:
• Patients presenting with splenomegaly/hepatosplenomegaly, cholestatic jaundice in neo-
nates or young infants, or neurologic or psychiatric symptoms
• Patients with a high clinical suspicion of NP-C
• Patients in at-risk clinical groups
In addition:
• When the initially selected biomarker does not show a profile consistent with that of
NP-C, additional biomarkers should be considered.
• Oxysterols may not be discriminatory in the presence of neonatal cholestasis34; bile
acid biomarkers may be more suitable for diagnostics in this population.11 Although
newborn screening is technically feasible and being explored, there is currently in-
sufficient evidence to recommend implementation, and ethical considerations must
first be accounted for.
• Biomarkers alone provide a very high suspicion of NP-C but diagnoses must be con-
firmed by genetic testing.
Current place of the filipin staining test
• The filipin staining test, the historical gold standard assay for NP-C diagnosis,30 is no
longer favored as the initial laboratory diagnostic test.
• The filipin staining test is a tool to assess the functional significance of new NPC1 or
NPC2 genetic variants, and helpful for confirming a diagnosis in patients for whom
genetic testing has not allowed identification of 2 pathogenic alleles30 (figure).
Molecular genetics and NP-C
• It is crucial to genetically confirm a diagnosis in patients with high clinical suspicion
and/or a biomarker profile consistent with NP-C.30
• Almost 700 variants, 400 of which are designated pathogenic mutations, are known
for NPC1 and 23 have been described for NPC2. The highly polymorphic nature of
NPC1 can confound diagnostic conclusions and make interpretation of new muta-
tions a challenge.
• The estimated proportion of NP-C cases in which detection of mutations on both alleles
can be reached using routine sequencing methods (exons and boundaries) is currently
higher than 90%.
It is crucial to genetically confirm a diagnosis in
patients with high clinical suspicion and/or
a biomarker profile consistent with NP-C.
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• It should be noted that some genetic changes, for example large deletions/duplications or
deep intronic changes, cannot be reliably identified by these methods.
• Detection of such mutations (estimated at ;5%) may therefore require other techniques
(see below). A small percentage of mutant NPC1 alleles (below 5%) has remained
unidentified in all experienced groups.35
• Pathogenic variants of NPC1 and NPC2 include point mutations that are detectable by
standard sequencing methods, and more complex mutations that require additional
techniques, as described below.
Traditional sequencing methods
• Sanger sequencing of genomic DNA (gDNA) or complementary DNA (cDNA) was
traditionally recommended, in parallel with the filipin staining test, to confirm a di-
agnosis of NP-C.1
NGS and gene panels
• NGS technologies provide accurate and sensitive methods for genetic analysis.
• The use of only high-quality reads and integrated software tools is essential. To assess
sensitivity, specificity, and reproducibility, all gene panels must be evaluated using
standardized samples (e.g., Genome in a Bottle samples). For further information, refer
to the following standards and guidelines: acmg.net/ACMG/Publications/Laboratory_
Standards___Guidelines/ACMG/Publications/Laboratory_Standards___Guidelines.aspx
and eurogentest.org/index.php?id5958.
• Targeted gene and multigene panels including NPC1 and NPC2, with complete exons
and exon–intron boundaries, can be used to screen clinical patient groups with an in-
creased risk of NP-C.
• NPC1 and NPC2 are included in several gene panels, including clinical exome, early-onset
ataxia,13,22 epilepsy, dystonia, infantile cholestasis,36 specific inborn errors of metabolism (e.g.,
lysosomal storage diseases), organic psychosis, early-onset cognitive decline, hepatospleno-
megaly, and developmental delay; new gene panels are in development.
• Diagnostic yield seems to be highest among patients with early-onset ataxia, where 1%–
2% of the patients have been found to have NP-C.13
• Prevalence of the other phenotypes mentioned above, even in clinically distinct patient
cohorts, is lower (,1%).37
• Panels in which all diagnostic target regions are not covered above a threshold that
ensures diagnosis must be reported, and if necessary, evaluated by another technology
(e.g., Sanger sequencing) to provide full coverage.
Complementary genetic tests
• In patients with high clinical suspicion and/or positive biomarker results, a negative or
heterozygous result from a primary genetic test (e.g., Sanger sequencing) should always
be questioned and confirmed by additional molecular studies able to detect complete or
partial gene deletions/duplications and deep intronic mutations.1,30
• Heterozygous complete or partial deletions/duplications of NPC1 or NPC2 require
quantitative techniques to assess copy numbers.30,38,39 Array comparative genomic hy-
bridization (CGH) can be used to detect large DNA dosage alterations. For DNA
dosage alterations below the array CGH platform resolution, quantitative real-time
A negative or heterozygous result from a primary
genetic test (e.g., Sanger sequencing) should
always be questioned
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PCR or multiplex ligation-dependent probe amplification should be used, to specifically
quantify NPC1 and NPC2 copy numbers.
• To detect deep intronic mutations, full-gene sequencing can be performed. Owing to
the polymorphic nature of intronic regions, cDNA analysis followed by the sequencing
of the specific intronic regions within the gDNA represents a highly preferred strategy.
Molecular genetics and NP-C diagnosis
• Table 2 shows an approach to the interpretation of molecular genetics results.
• Online databases should be used to record and assess the pathogenicity of mutations
(e.g., NPC-db2 database in Tübingen; see medgen.medizin.uni-tuebingen.de/NPC-db2/
index.php).
• Adherence to the American College of Medical Genetics and Genomics guidelines is
recommended for assessment and reporting of new mutations.
Mutations and genotype/phenotype associations
• The 2 most frequent NPC1 mutations reported worldwide are p.I1061T (c.3182T,C in
exon 21), accounting for 20% of mutant alleles in Western Europeans, and p.P1007A,
also prevalent in patients of European descent.40 A number of recurrent mutations are
highly prevalent in patients originating from particular countries.
• Some NPC1 mutations (including p.P1007A) are associated with less pronounced cho-
lesterol trafficking alterations (variant filipin profile).30
• A few missense mutations appear to be clearly associated with a late-onset form of NP-
C, even in compound heterozygosity with a very severe/null allele.
• In the NPC2 gene, 23 disease-causing mutations (including a large deletion) have been
described; the majority are severe, leading to a truncated protein and null alleles, but
some (p.V39M and p.P120S) lead to later-onset forms.
A revised laboratory diagnostic algorithm for the use of
biomarkers and genetic testing in NP-C
• Clinical assessment and symptom profiling are important in guiding physicians to
suspect NP-C.
Table 2 Recommendations for diagnosis of patients identified by molecular genetic screening for NPC1 and NPC2
Genetic finding Recommendations
2 Pathogenic mutations Confirm compound heterozygosity by allele segregation in parents
1 Pathogenic mutation 1 1 VUS Confirm compound heterozygosity by allele segregation in parents
Confirm high clinical suspicion of NP-C (clinical signs and biomarker profile) and perform
filipin staining test
Perform additional molecular genetic tests (e.g., full-gene sequencing, DNA array, MLPA,
qPCR, cDNA sequencing) to identify further mutant alleles
1 Pathogenic mutation only
or 1 VUS only
Confirm high clinical suspicion of NP-C (clinical signs and biomarker profile) and perform
filipin staining test
Perform additional molecular genetic tests (e.g., full-gene sequencing, DNA array, MLPA,
qPCR, cDNA sequencing) to identify further mutant alleles
0 Pathogenic mutations Perform additional molecular genetic tests (e.g., full-gene sequencing, DNA array, MLPA,
qPCR, cDNA sequencing) to identify hidden mutant alleles
Confirm high clinical suspicion of NP-C (clinical signs and biomarker profiles) and perform
filipin staining test
Abbreviations: cDNA 5 complementary DNA; MLPA 5 multiplex ligation-dependent probe amplification; NP-C 5 Niemann-Pick
disease type C; qPCR 5 quantitative PCR; VUS 5 variant of unknown significance.
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• The previous diagnostic algorithm has been revised to reflect our understanding of the
value in screening not only individual patients with a high clinical suspicion of NP-C
but also clinical patient groups with an increased risk of NP-C, the availability of
diagnostic biomarkers for NP-C, and advancements in molecular genetics. An updated
diagnostic algorithm reflecting current best practice is shown in the figure.
• Positive genetic testing results, or positive biomarker testing results combined with
molecular genetic analysis, are now deemed sufficient to diagnose NP-C in most cases.
• Local factors (e.g., availability of, and access to, services) determine the choice and order
of diagnostic tests.
Treatment
• Miglustat (Zavesca; Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) therapy
for existing neurologic manifestations should be considered, as discussed in the
previous recommendations.1
Disease monitoring
• Neurologic function and quality of life should be monitored, as outlined in the previous
recommendations.1
Future considerations
• There is no single biomarker specific for NP-C. Combining biomarkers that reflect
defective cholesterol trafficking/oxidative stress with lysosphingolipid biomarkers could
improve screening specificity. Sensitivity has not yet been evaluated for biomarker
combinations.
• NP-C is a global disease, yet expert testing laboratories are not available in every
country. Diagnostic workflows should include easy, robust, and inexpensive sampling,
shipment, and storage technologies; DBS filtercards, shown to offer genetic and bio-
chemical value for NP-C, should be evaluated for a more general approach.
• With the advent of whole-genome sequencing, interpretation tools for variants of un-
known significance require improvement by systematically establishing functional assays
for missense and splicing mutations or transcriptional failure.
• Incorporation of NP-C biomarker tests into routine panels (e.g., metabolic) for screen-
ing in populations with increased risk of NP-C, in particular neonates with cholestasis
and hepatosplenomegaly, could facilitate earlier diagnosis.
• Better understanding of the genotype–phenotype correlation in NP-C will allow a per-
sonalized approach to treatment.
• Currently, miglustat is the only approved therapy for patients with NP-C. Other treat-
ments are undergoing investigation.
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